Immune checkpoint inhibitors (ICI) targeting the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis have significantly improved the survival of patients with advanced NSCLC [5, 6]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.